# Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer

Source: https://onco.cc/trials/nct07527858/  
OnCo record `nct07527858` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Nivolumab, Bevacizumab in colorectal cancer, run by Gilead Sciences, now recruiting.

## Summary

Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer is a phase 2 interventional study registered as NCT07527858 by Gilead Sciences, with 170 participants planned, started 2026-05-19 and due to reach its primary completion in 2028-12. Interventions recorded: Denikitug, Nivolumab, Bevacizumab, Trifluridine-Tipiracil. Conditions listed: Advanced Microsatellite Stable Colorectal Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07527858
- Phase: 2
- Setting: A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
- Sponsor: Gilead Sciences
- Enrolled: 170

## Sources

- ClinicalTrials.gov NCT07527858: https://clinicaltrials.gov/study/NCT07527858

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- companies: [Gilead Sciences (incl. Kite)](https://onco.cc/companies/gilead/)

---
JSON: https://onco.cc/api/v1/entities/nct07527858.json